Prioritizing Patient Care, Safety Through Integrated Technology

Oct 12, 2021

Pharmacy Times spoke with Dr. Jeffrey Akers, CEO of Pharmaceutical Services at Appalachian Regional Healthcare, about how integrated technology can empower pharmacists to prioritize patient care and safety and can help prevent harmful medication events from occurring.

Pharmacy Times spoke with Dr. Jeffrey Akers, CEO of Pharmaceutical Services at Appalachian Regional Healthcare, about how integrated technology can empower pharmacists to prioritize patient care and safety and can help prevent harmful medication events from occurring.

Related Videos

Pharmacist helping patient | Image credit: Zamrznuti tonovi - stock.adobe.com

Healthcare technology | Image credit: ipopba | stock.adobe.com

Pharmacist in home infusion environment | Image credit: Satjawat - stock.adobe.com

Gastroenterologist using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com

Supreme Court | Image credit: steheap - stock.adobe.com

Related Content

Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression

Pharmacy Focus: Student Edition - Creatives in Pharmacy

FDA Approves New Indication for Letermovir for Prevention of Cytomegalovirus in Adult Kidney Transplant Recipients

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression

Pharmacy Focus: Student Edition - Creatives in Pharmacy

FDA Approves New Indication for Letermovir for Prevention of Cytomegalovirus in Adult Kidney Transplant Recipients

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression

Pharmacy Focus: Student Edition - Creatives in Pharmacy

FDA Approves New Indication for Letermovir for Prevention of Cytomegalovirus in Adult Kidney Transplant Recipients

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Related Content

Antibodies attack a cancer cell or virus | Image Credit: Design Cells - stock.adobe.com

Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression

Pharmacy Focus: Student Edition - Creatives in Pharmacy

Pharmacy Focus: Student Edition - Creatives in Pharmacy

FDA Approves New Indication for Letermovir for Prevention of Cytomegalovirus in Adult Kidney Transplant Recipients

FDA Approves New Indication for Letermovir for Prevention of Cytomegalovirus in Adult Kidney Transplant Recipients

Pharmacy Focus: Oncology Edition

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Hodgkin's lymphoma, light micrograph, photo under microscope. Credit: Dr_Microbe - stock.adobe.com

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

Credit: Robert - stock.adobe.com

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.